---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-015901"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2025-04-01T23:59:59+00:00"
generated_at: "2026-05-24T00:38:40.262986+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Esperion appoints Robert E. Hoffman to board; two directors resign effective June 1

## Summary
- Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D.Phil. resign from board effective June 1, 2025; no disagreement cited.
- Robert E. Hoffman elected independent director effective April 1, 2025; will chair Audit Committee from May 29, 2025.
- Hoffman brings CFO and CEO experience from Heron, AnaptysBio, Arena, Kintara, and multiple biotech boards.

## SEC filing metadata
- accession: 0001628280-25-015901
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2025-04-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828025015901/0001628280-25-015901-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828025015901/espr-20250401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-015901
- JSON: https://secwatch.observer/filing/0001628280-25-015901.json
- Plain text: https://secwatch.observer/filing/0001628280-25-015901.txt

## Key facts
- Executive change
  Antonio M. Gotto, Jr., M.D., D.Phil. resigned as Director at Esperion Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On April 1, 2025, Antonio M. Gotto, Jr., M.D., D. Phil. notified the Board of the Company of his decision to resign from the Board, including his position as a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), effective June 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828025015901/0001628280-25-015901-index.htm
- Executive change
  Nicole Vitullo resigned as Director at Esperion Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On April 1, 2025, Nicole Vitullo notified the Board of Directors (the “Board”) of Esperion Therapeutics, Inc. (the “Company”) of her decision to resign from the Board, including her positions as a member of the Audit Committee of the Board (the “Audit Committee”) and Compliance Committee of the Board, effective June 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828025015901/0001628280-25-015901-index.htm
- Executive change
  Robert E. Hoffman was elected as Director and Chairperson of the Audit Committee at Esperion Therapeutics, Inc..
  - Action: elected
  - Role: Director and Chairperson of the Audit Committee
  source text: On April 1, 2025, upon the recommendation of the Nominating and Corporate Governance Committee, the Board elected Robert E. Hoffman to the Board, effective April 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828025015901/0001628280-25-015901-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.